Funding and Growth Potential Kernal Biologics recently secured $25 million in Series A financing, indicating strong investor interest and growth potential for the company. This funding can be leveraged to expand operations, drive further research, and potentially explore new market opportunities.
Strategic Partnerships Kernal Biologics has established partnerships with companies like Amgenbd, Hummingbird Ventures, and Rjhbiosciences. These collaborations signify trust in Kernal's technology and create avenues for joint sales initiatives or cross-promotional activities to tap into new markets.
Cutting-Edge mRNA Technology With a focus on messenger RNA technology beyond vaccines, Kernal Biologics is positioned as a pioneer in the mRNA 2.0 space. Highlighting the advanced nature of their therapies can attract the attention of healthcare providers, pharmaceutical companies, and research institutions looking for innovative solutions.
Competitive Landscape Analysis Analyzing the landscape of similar companies like TARA Biosystems, Repare Therapeutics, and Dewpoint Therapeutics provides insights into market positioning. Identifying key differentiators and addressing unmet needs in comparison to competitors can help in crafting targeted sales strategies.
Market Expansion Opportunities Situated in Cambridge, Massachusetts, a hub for biotechnology research, Kernal Biologics is well-placed to capitalize on the thriving life sciences ecosystem. Actively engaging with local industry events, conferences, and networking opportunities can open doors to potential collaborations and business expansions.
11
160
$10M$50M
129$10M$50M
65$10M$50M
2$10M
34$10M
138$10M$50M
86$10M$50MKernal Biologics uses 8 technology products and services including Google Analytics, Lodash, Zepto, and more. Explore Kernal Biologics's tech stack below.
| Kernal Biologics Email Formats | Percentage |
| First.Last@kernalbio.com | 76% |
| First@kernalbio.com | 13% |
| Last@kernalbio.com | 7% |
| L.First@kernalbio.com | 4% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.
Company Overview
Media & News
Funding & FinancialsKernal Biologics has raised a total of $25M of funding over 6 rounds. Their latest funding round was raised on Jul 07, 2022 in the amount of $25M.
Kernal Biologics's revenue is in the range of $10M
Funding & FinancialsKernal Biologics has raised a total of $25M of funding over 6 rounds. Their latest funding round was raised on Jul 07, 2022 in the amount of $25M.
Kernal Biologics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com